Investing $20 million in a new building and the renovation of the
existing office space
LAVAL, Dec. 5 /CNW Telbec/ - Roche Diagnostics today inaugurated its new
head office in Laval, Quebec. Roche has invested $20 million in the
construction of a new 26,230 square feet building and the renovation of the
existing office space.
The inaugural event was attended by local government officials, economic
leaders, media and employees.
"This investment not only demonstrates our confidence in the future of
our business in Canada but also reflects our ambition to do an ever-better job
of serving our Canadian customers in the years ahead," said Dr. Severin
Schwan, Chief Executive Officer of the Diagnostics division of Roche. "For
many years, new tests and technologies were regarded as cost drivers. But
looking at the treatment process as a whole, it is clear that innovative
diagnostics can help make healthcare delivery more cost-effective - precisely
because they contribute to sounder medical decisions. They can help physicians
tailor treatments to patients' individual needs."
"This expansion is the result of our success over the last 10 years as
Roche Diagnostics has become the in-vitro diagnostic market leader," said
Christopher Parker, President and General Manager, Roche Diagnostics (Canada).
" By doubling the size of our office space, we will be able to provide an
enhanced level of customer service and product support across the country.
These are central elements that will enable us to further extend our market
In Canada, Roche Diagnostics markets, sells and distributes a wide array
of innovative products and services to laboratories, hospitals, researchers
and patients. It employs 400 people.
About Roche and the Roche Diagnostics Division
Headquartered in Basel, Switzerland, Roche is one of the world's leading
research-focused healthcare groups in the fields of pharmaceuticals and
diagnostics. As the world's biggest biotech company and an innovator of
products and services for the early detection, prevention, diagnosis and
treatment of diseases, the Group contributes on a broad range of fronts to
improving people's health and quality of life. Roche is the world leader in
in-vitro diagnostics and drugs for cancer and transplantation, a market leader
in virology and active in other major therapeutic areas such as autoimmune
diseases, inflammation, metabolic disorders and diseases of the central
nervous system. In 2006 sales by the Pharmaceuticals Division totalled
33.3 billion Swiss francs, and the Diagnostics Division posted sales of
8.7 billion Swiss francs. Roche has R&D agreements and strategic alliances
with numerous partners, including majority ownership interests in Genentech
and Chugai, and invests approximately 7 billion Swiss francs a year in R&D.
Worldwide, the Group employs about 75,000 people. Additional information is
available on the Internet at www.roche.com and www.rochediagnostics.ca.
/NOTE TO PHOTO EDITORS: A photo accompanying this release is available on
the CNW Photo Network and archived at http://photos.newswire.ca.
Additional archived images are also available on the CNW Photo Archive
website at http://photos.newswire.ca. Images are free to accredited
members of the media/
For further information:
For further information: Michèle Beaubien, Communications, (450) 686